Related Experiment Video
Updated: Nov 18, 2025

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
ELOVL5 Is a Critical and Targetable Fatty Acid Elongase in Prostate Cancer
Margaret M Centenera1,2,3, Julia S Scott1,2,3, Jelle Machiels4
1University of Adelaide Medical School, Adelaide, SA, Australia.
Androgen receptor (AR) signaling in prostate cancer drives increased fatty acid chain length via ELOVL5, promoting tumor growth and metastasis. Targeting this lipid metabolism pathway offers a new therapeutic vulnerability for advanced prostate cancer.
Area of Science:
- Oncology
- Molecular Biology
- Metabolic Research
Background:
- Androgen receptor (AR) is a key driver in prostate cancer, but metastatic outcomes remain poor.
- Understanding AR-regulated cellular processes is crucial for developing new therapies.
- Lipid metabolism is a known hallmark of AR signaling, but its specific role is undefined.
Purpose of the Study:
- To define the relationship between AR signaling and the lipidome in prostate cancer.
- To investigate the role of fatty acid elongation in AR-driven prostate cancer.
- To identify novel therapeutic targets within AR-regulated metabolic pathways.
Main Methods:
- Mass spectrometry-based lipidomics to analyze lipid profiles.
- Investigated the induction of ELOVL fatty acid elongase 5 (ELOVL5) by AR.
- Assessed ELOVL5 expression in prostate cancer cells, xenografts, and clinical samples.
- Studied the effects of ELOVL5 depletion and cis-vaccenic acid supplementation.
Main Results:
- Prostate cancer cells exhibit increased phospholipid fatty acyl chain length, regulated by AR.
- AR directly induces ELOVL5, which is upregulated in prostate cancer.
- ELOVL5 depletion impairs mitochondrial function, increases reactive oxygen species, and suppresses tumor growth and metastasis.
- Supplementation with cis-vaccenic acid reversed the effects of ELOVL5 knockdown.
Conclusions:
- Phospholipid elongation via ELOVL5 is a protumorigenic, AR-regulated metabolic pathway in prostate cancer.
- ELOVL5 is critical for tumor growth, metastasis, and is a potential therapeutic target.
- Targeting lipid elongation presents a novel strategy for treating metastatic prostate cancer.
Related Concept Videos
Tail-anchoring of Proteins in the ER Membrane
Lipid Catabolism
Overview of Fatty Acid Metabolism
Fatty acids are catabolized in a process called beta-oxidation, which takes place in the matrix of the mitochondria and converts their fatty acid chains into two-carbon units of acetyl groups. The acetyl...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Directing Proteins to the Rough Endoplasmic Reticulum
Lipid Digestion

